Literature DB >> 11253284

[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].

T Szucs1, M Behrens, T Volmer.   

Abstract

Influenza is often seen as an unproblematic and self-limiting disease despite putting a high burden on patients as well as being of high socio-economic relevance to societies. This analysis aims to visualize that influenza deserves a rise in attention especially because of its socio-economic relevance, based on a transparent methodology. This analysis investigates the costs caused by influenza in Germany in 1996. The analysis is based on a costs model that takes in official aggregated statistical and publicly available data. A top-down approach based on the ICD-9 Code 487 is used. The costs of influenza in 1996 came to nearly DM 5 billion. Only a small proportion of this was due to direct treatment costs (DM 0.6 billion). The direct costs are made up of 304 million DM (52.8%) for ambulatory care, 214 million DM (37.1%) for prescription-only and OTC medication, and 58 million DM (10.1%) for inpatient treatment including rehabilitation measures. The bulk of the indirect costs, some DM 4.4 billion (99.5%), was due to unfitness for work, whereas only about 21 million DM (0.5%) was accounted for by occupational disability and deaths. On the basis of an estimated 4 million cases of influenza in 1996 (no epidemics), the costs work out at about 1,237 DM per patient per year. In the event of an epidemic, the German economy would be faced with correspondingly higher costs of over DM 10.5 billion. Effective prevention and treatment strategies such as better pre-season vaccination rates, early diagnosis and effective antiviral therapy can help to reduce this financial burden.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253284     DOI: 10.1007/pl00002180

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  6 in total

1.  Trends of out-of-pocket expenditure for influenza in China Health and Nutrition Survey during 1989-2006.

Authors:  Jinan Liu; Lizheng Shi; Mahmud Khan; Lingzhong Xu; Liya Wang
Journal:  Int J Public Health       Date:  2011-04-19       Impact factor: 3.380

2.  Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany.

Authors:  Oliver Damm; Martin Eichner; Markus Andreas Rose; Markus Knuf; Peter Wutzler; Johannes Günter Liese; Hagen Krüger; Wolfgang Greiner
Journal:  Eur J Health Econ       Date:  2014-05-25

3.  Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012.

Authors:  Birgit Ehlken; Anastassia Anastassopoulou; Johannes Hain; Claudia Schröder; Klaus Wahle
Journal:  BMC Public Health       Date:  2015-06-21       Impact factor: 3.295

4.  Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013.

Authors:  Jennifer Haas; Sebastian Braun; Peter Wutzler
Journal:  Eur J Health Econ       Date:  2015-07-05

5.  Rationale and opportunities in estimating the economic burden of seasonal influenza across countries using a standardized WHO tool and manual.

Authors:  Nathorn Chaiyakunapruk; Surachai Kotirum; Anthony T Newall; Philipp Lambach; Raymond C W Hutubessy
Journal:  Influenza Other Respir Viruses       Date:  2017-11-16       Impact factor: 4.380

6.  Direct and indirect cost of COVID-19 patients in Iran.

Authors:  Karim Nakhaei; Habib Jalilian; Morteza Arab-Zozani; Somayeh Heydari; Leila Torkzadeh; Masoomeh Taji
Journal:  Health Policy Technol       Date:  2021-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.